Does it work? The exact care matters

A useful study compares two clear treatments

Joint soreness can change with rest, lighter activity, and time. So researchers compare people given the new procedure with people given another kind of care.

For example, one group might receive prepared bone marrow while another gets a common steroid. The difference in pain and movement helps show what the new procedure added.

One large knee study found no extra pain relief

One large knee study followed 480 people with osteoarthritis, the wear-and-tear arthritis your doctor may mention, so researchers could directly compare pain after several treatments when twelve months had passed. Some got preparations made from bone marrow, fat, or donated cord tissue.

Other people got corticosteroid, a common steroid used for short-term joint relief. At twelve months, the prepared cells didn't give clearer pain relief than the steroid.

Some smaller studies found less pain or easier movement after other cell preparations. Those mixed results can't promise what one clinic procedure will do for you.

QC Kinetix can explain exactly what it offers

QC Kinetix provides regenerative treatment options, office procedures that may use fluid prepared from blood, bone marrow, or fat. Its medical providers, the licensed clinic staff, examine your joint before discussing those choices.

Ask which fluid would be prepared, where it would be placed, and which study tested it. Get the complete price and visit count in writing before deciding.

You can hear the answers without agreeing to care that day. If the explanation isn't clear, ask your own doctor for another view.

Less soreness should mean easier daily movement

A form can say pain fell without showing whether life got easier. Ask whether people slept better, climbed stairs, or walked farther.

Choose one movement you want back, then decide when to check it. If the treatment doesn't help that movement, ask what happens next.

The cost makes more sense when it's tied to a task you value. Don't accept “better scores” without hearing what got better.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample.

   Cao M, et al. — Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2025. DOI: 10.1186/s13287-025-04252-2.

3. A phase III double-blind placebo-controlled trial in 261 patients with Kellgren-Lawrence grade 3 knee osteoarthritis tested a single injection of autologous culture-expanded adipose-derived mesenchymal stem cells - a product that cannot legally be sold outside a clinical trial in the United States because culture expansion is more than minimal manipulation.

   Kim KI, et al. — Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial. Am J Sports Med, 2023. DOI: 10.1177/03635465231179223.

4. A phase 3 placebo-controlled trial of 146 patients using allogeneic bone marrow-derived MSCs (25 million cells) plus hyaluronic acid reported significant WOMAC improvement versus placebo at 6 and 12 months, with a roughly 24 percent relative change - one of the more favourable trials, and it used a culture-expanded product administered with hyaluronic acid rather than a same-day clinic preparation.

   Gupta PK, et al. — Efficacy and Safety of Stempeucel in Osteoarthritis of the Knee: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study. Am J Sports Med, 2023. DOI: 10.1177/03635465231180323.

5. A controlled randomized phase I/II trial in 26 patients found repeated dosing of culture-expanded umbilical cord-derived MSCs at baseline and 6 months produced lower WOMAC pain at 12 months (1.1 +/- 1.3) than hyaluronic acid (4.3 +/- 3.5), while a single MSC dose did not separate from hyaluronic acid.

   Matas J, et al. — Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial. Stem Cells Transl Med, 2019. DOI: 10.1002/sctm.18-0053.

6. A phase IIb double-blind randomized trial of just 24 knees reported WOMAC improvement at 6 months after a single autologous adipose-derived MSC injection while saline controls did not improve - a positive but very small trial, of the kind that dominates this literature.

   Lee WS, et al. — Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, Placebo-Controlled Clinical Trial. Stem Cells Transl Med, 2019. DOI: 10.1002/sctm.18-0122.

7. A 2023 appraisal of 15 randomized and 11 non-randomized trials of culture-expanded MSCs for knee osteoarthritis found function improved relative to control in 11 of 15 RCTs and cartilage protection or repair reported in 18 of 21 imaging studies, but noted the total sample of 610 patients limits any definitive conclusion.

   Copp G, et al. — Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success. Cell Mol Immunol, 2023. DOI: 10.1038/s41423-023-01020-1.

8. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.